Want to see GB:CREO full AI Analyst Report?
Top Page
Creo Medical
(LSE:CREO)
Select Model
Select Model
Rating:49Neutral
Price Target:
13.00 p
▲(0.00% Upside)
Action:Reiterated
Date:08/24/26
The score is primarily held back by weak financial performance—large ongoing operating losses and sustained negative operating/free cash flow—despite a relatively conservative balance sheet. Technical indicators are mixed/neutral, offering limited momentum support. Valuation (P/E ~10.3) is a modest positive but not enough to offset the core profitability and cash-burn risks.
Positive Factors
Manageable Leverage
Low leverage and a sizable equity base provide financial flexibility for continued commercialisation and product investment. This reduces near-term balance-sheet pressure, although ongoing losses could gradually weaken that cushion.
Negative Factors
Persistent Operating Losses
Large recurring operating losses show that the cost base remains well ahead of current revenue scale. Unless commercial growth accelerates or spending becomes more efficient, profitability could remain structurally distant.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Low leverage and a sizable equity base provide financial flexibility for continued commercialisation and product investment. This reduces near-term balance-sheet pressure, although ongoing losses could gradually weaken that cushion.
Read all positive factors
Creo Medical (CREO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£55.58M
Dividend YieldN/A
Average Volume (3M)565.36K
Price to Earnings (P/E)9.8
Beta (1Y)1.09
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees104
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.01
Shares Outstanding449,139,980
10 Day Avg. Volume442,698
30 Day Avg. Volume565,357
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.82
Price to Sales (P/S)6.81
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£9.10M
Creo Medical Business Overview & Revenue Model
Company Description
Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headq...
How the Company Makes Money
Creo Medical generates revenue primarily from commercialising its endoscopic therapy platform and related devices. Key revenue streams include: (1) sales of capital equipment, such as its CROMA generator/platform systems used by hospitals and endo...
Creo Medical Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.00M | 4.00M | 30.80M | 27.17M | 25.16M |
| Gross Profit | 1.40M | 1.90M | 15.30M | 10.01M | 9.02M |
| EBITDA | -19.70M | -26.10M | -20.70M | -27.62M | -27.54M |
| Net Income | 5.30M | -28.70M | -21.70M | -26.94M | -24.59M |
Balance Sheet | |||||
| Total Assets | 59.10M | 65.00M | 76.60M | 75.34M | 100.61M |
| Cash, Cash Equivalents and Short-Term Investments | 12.40M | 8.70M | 18.50M | 13.10M | 43.53M |
| Total Debt | 4.10M | 4.40M | 8.30M | 11.70M | 10.56M |
| Total Liabilities | 9.10M | 22.60M | 16.80M | 25.93M | 27.29M |
| Stockholders Equity | 50.00M | 42.40M | 59.80M | 49.40M | 73.32M |
Cash Flow | |||||
| Free Cash Flow | -20.00M | -22.60M | -22.80M | -28.26M | -32.10M |
| Operating Cash Flow | -19.10M | -22.20M | -21.60M | -24.99M | -25.98M |
| Investing Cash Flow | 19.40M | 15.30M | -18.30M | -6.03M | -7.87M |
| Financing Cash Flow | -700.00K | 16.20M | 29.80M | 400.00K | 31.99M |
Creo Medical Technical Analysis
Negative
13.00
Price Trends
13.30
Negative
13.24
Negative
12.91
Negative
Market Momentum
-0.17
Positive
34.21
Neutral
19.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Negative. The current price of 13 is above the 20-day moving average (MA) of 12.81, below the 50-day MA of 13.30, and above the 200-day MA of 12.91, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 34.21 is Neutral, neither overbought nor oversold. The STOCH value of 19.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CREO.
Creo Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | £607.01M | 60.71 | 3.87% | 1.67% | 28.96% | 39.58% | |
68 Neutral | £191.09M | 24.12 | 23.64% | 3.57% | 13.71% | 27.65% | |
68 Neutral | £8.44B | 17.95 | 12.25% | 2.88% | 2.17% | 27.33% | |
55 Neutral | £3.96M | -4.25 | -11.04% | ― | -2.87% | 52.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £55.58M | 9.82 | 9.56% | ― | ― | ― |
* Healthcare Sector Average
GB:CREO
Creo Medical
12.38
0.13
1.02%
GB:AMS
Advanced Medical Solutions
280.50
79.64
39.65%
GB:SUN
Surgical Innovations
0.43
-0.27
-39.29%
GB:TSTL
Tristel
397.50
51.17
14.78%
GB:SN
Smith & Nephew
1,008.50
-344.49
-25.46%
Creo Medical Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Creo Medical lifts H1 revenue 45% as cost cuts and financing sharpen path to profitability
Positive
Jul 28, 2026
Creo Medical reported a 45% rise in first-half 2026 revenue to £3.2m, driven by growing adoption of its minimally invasive endoscopy devices and expansion into new regions, particularly Latin America. The company maintained its guidance for f...
Business Operations and StrategyProduct-Related Announcements
Creo Medical’s MicroBlate Flex Surpasses 100 Clinical Cases in Early Lung Cancer Care
Positive
Jul 23, 2026
Creo Medical has passed a key milestone in the rollout of its MicroBlate Flex flexible microwave ablation device, with more than 100 clinical cases now completed across leading centres in the UK and Europe. Designed for precise treatment of soft t...
Business Operations and StrategyExecutive/Board Changes
Creo Medical Allocates Incentive Plan Shares to Executives Without New Issuance
Positive
Jul 6, 2026
Creo Medical has reported share acquisitions and awards under its HMRC-approved Share Incentive Plan, which is offered to all UK employees including directors. The plan uses existing unallocated ordinary shares held in trust, meaning no new shares...
Business Operations and StrategyShareholder Meetings
Creo Medical shareholders back all AGM resolutions, supporting endoscopy tech strategy
Positive
Jun 29, 2026
Creo Medical Group said shareholders approved all resolutions at its annual general meeting, ensuring continuity of governance and strategic direction for the AIM-quoted medical device maker. The company plans to publish detailed voting results on...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Creo Medical lifts growth outlook as strong Q1 sales and cost cuts bolster expansion drive
Positive
Jun 29, 2026
Creo Medical reported that strong sales momentum from FY25 has carried into FY26, with first-quarter revenue rising about 60% year-on-year on the back of growing clinical adoption and higher procedural volumes. Management now expects full-year FY2...
Business Operations and Strategy
Creo Medical appoints Shore Capital as adviser and broker
Positive
Jun 23, 2026
Creo Medical Group has appointed Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers Limited as its sole corporate broker with immediate effect. The move formalises a new advisory and broking relationship th...
Financial DisclosuresShareholder Meetings
Creo Medical Posts 2025 Annual Report and Sets June AGM
Neutral
Jun 4, 2026
Creo Medical Group has published its 2025 Annual Report and Accounts and the notice of its upcoming Annual General Meeting on its website, with hard copies sent to shareholders who opted for physical mail. The AGM is scheduled for 29 June 2026 in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.